In mesenchymal tumors, IDH mutations are present in about half of central cartilaginous tumors: in 52% of central low-grade, 58.9% of G2-G3 CCBC, and 56.5% of dedifferentiated chondrosarcoma [5]. Here, IDH2 is linked to chondrogenic neoplasm.